...
首页> 外文期刊>AIDS >Combining human antisera to human leukocyte antigens, HIVgp120 and 70 kDa heat shock protein results in broadly neutralizing activity to HIV-1.
【24h】

Combining human antisera to human leukocyte antigens, HIVgp120 and 70 kDa heat shock protein results in broadly neutralizing activity to HIV-1.

机译:将人抗血清与人白细胞抗原,HIVgp120和70 kDa热休克蛋白结合使用,可产生对HIV-1的广泛中和活性。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE: To elicit broadly neutralizing antibody activity by combining polyclonal human serum IgG antibodies with HIVgp120, human leukocyte antigen (HLA) class I or class II and 70 kDa heat shock protein. DESIGN:: In addition to HIV antigens, HIV-1 virions express HLA class I, HLA class II and 70 kDa heat shock protein molecules, which have quantitative and functional significance. The complementary effect of combining human polyclonal IgG antibodies with these antigens may result in effective broad spectrum neutralizing activity. METHODS: Polyclonal human sera with IgG antibodies and monoclonal antibody to HLA class I or class II, HIVgp120 and 70 kDa heat shock protein were selected and used in single, double or triple combinations. Dose-dependent inhibition studies of HIV-1 clades A, B, C and D were carried out using human CD4 T cells treated with the combinations of human sera and with monoclonal antibodies for clade B. The results are presented as half maximal (IC50) inhibitory concentration and maximum inhibition by these sera. RESULTS: The half maximal (IC50) inhibitory concentration of clade B HIV-1 infection with single or a combination of two antisera was higher than those with three antisera, which also showed maximum inhibition of HIV-1. Further investigations of human sera with HIV-1 clades C and D also showed lower half maximal (IC50) inhibitory concentrations and higher maximum inhibition with combinations of the three antisera, but this was not seen with clade A. CONCLUSION: A novel vaccination strategy eliciting broadly neutralizing antibody activity to the CCR5-using HIV-1 clades B, C and D has been demonstrated by the trimolecular complex of human antisera with HLA class II or class I, HIVgp120 and 70 kDa heat shock protein.
机译:目的:通过将多克隆人血清IgG抗体与HIVgp120,I类或II类白细胞抗原(HLA)和70 kDa热休克蛋白结合,广泛地中和抗体活性。设计:除了HIV抗原外,HIV-1病毒体还表达I类HLA,II类HLA和70 kDa热激蛋白分子,具有定量和功能意义。将人多克隆IgG抗体与这些抗原结合起来的互补作用可能会导致有效的广谱中和活性。方法:选择具有IgG抗体和针对HLA I类或II类,HIVgp120和70 kDa热激蛋白的单克隆抗体的多克隆人血清,并以单,双或三联形式使用。 HIV-1进化枝A,B,C和D的剂量依赖性抑制研究是使用经人血清和进化枝B单克隆抗体处理的人CD4 T细胞进行的。结果显示为一半最大值(IC50)抑制浓度和这些血清的最大抑制作用。结果:单一或两种抗血清联合感染的进化枝B HIV-1感染的最大半数抑制浓度(IC50)高于三种抗血清对HIV-1感染的最大抑制浓度,对HIV-1的抑制作用最大。对具有HIV-1进化枝C和D的人血清的进一步研究还显示,三种抗血清的组合具有较低的最大半数(IC50)抑制浓度和较高的最大抑制作用,但是在进化枝A中却未见此结论。人类抗血清的三分子复合物与HLA II类或I类HIVgp120和70 kDa热休克蛋白已证明,使用HIV-1进化枝B,C和D广泛中和了针对CCR5的抗体活性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号